Rossari Biotech IPO: A diversified portfolio, expansion are key triggers

The expansion is expected to support growth with revenues and profits estimated to rise by 20-25 per cent over the FY20-23 period

Investor demand for specialty chemicals maker Rossari Biotech has been strong resulting in listing day gains of 75 per cent and a 143 per cent rise till date. A diversified product portfolio, emphasis on research and development, and expansion are the key triggers.
 

One segment that has helped this business-to-business supplier is home, personal and performance chemicals (HPPC), which accounted for 47 per cent of FY20 revenues and has been the main contributor of top line and margin expansion over the last few years.
 

Aided by a 95 per cent compound annual growth rate of HPPC during FY17-20, the company